0001900304 2026-08-13 2026-08-13 0001900304 1 2026-08-13 2026-08-13 0001900304 2 2026-08-13 2026-08-13 0001900304 3 2026-08-13 2026-08-13 0001900304 4 2026-08-13 2026-08-13 0001900304 1 2026-08-13 2026-08-13 0001900304 2 2026-08-13 2026-08-13 iso4217:USD pure shares F-3 424B5 EX-FILING FEES 333-297789 0001900304 Haleon plc N/A true false F-3 Haleon plc false Debt 4.625% Senior Fixed Rate Notes due 2029 of Haleon US Capital LLC true 598056000.00 0.0001381 82591.53 false Debt 4.875% Senior Fixed Rate Notes due 2031 of Haleon US Capital LLC true 597426000.00 0.0001381 82504.53 false Debt 5.375% Senior Fixed Rate Notes due 2036 of Haleon US Capital LLC true 793352000.00 0.0001381 109561.91 false Debt Guarantees of Haleon plc true 0.0001381 0.00 1988834000.00 274657.97 0.00 274657.97 0.00 The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. The maximum aggregate amount of that offering is $2,000,000,000. See Offering Note 1. See Offering Note 1. Haleon plc will fully and unconditionally guarantee the 4.625% Senior Fixed Rate Notes due 2029, 4.875% Senior Fixed Rate Notes due 2031 and 5.375% Senior Fixed Rate Notes due 2036 issued by Haleon US Capital LLC. Pursuant to Rule 457(n) under the Securities Act of 1933, as amended, no separate filing fee is required for the guarantees. true Haleon plc F-1 333-266358 2022-07-28 274657.97 Equity Ordinary Shares, nominal value GBP0.01 per share 3119828916 11418573832.56 true Haleon plc F-1 333-266358 2022-07-28 1409122.35 Haleon plc previously filed a registration statement on Form F-1 (File No. 333-266358), initially filed on July 28, 2022, amended on August 5, 2022 and initially declared effective on August 9, 2022 (the "2022 Registration Statement"), which registered 4,150,383,736 Ordinary Shares (in the form of Ordinary Shares or American Depositary Receipts representing Ordinary Shares) for sale by the Selling Securityholders named therein, including GSK plc and certain of its controlled undertakings ("GSK") and Pfizer Inc. ("Pfizer"), for a proposed maximum aggregate offering price of $15,200,888,343.08. The 2022 Registration Statement was not used and on May 11, 2023, GSK resold an aggregate amount of 240,000,000 previously registered Ordinary Shares outside the United States pursuant to Regulation S under the Securities Act. Accounting for this transaction, 3,910,383,736 Ordinary Shares were not sold under the 2022 Registration Statement, resulting in an available fee offset of $1,326,722.81. The Registrants and Haleon UK Capital plc filed a registration statement on Form F-3 (File No.333-273103), which was filed and became automatically effective on July 3, 2023 (the "2023 Registration Statement"). Pursuant to Rule 457(p) under the Securities Act, the Registrants and Haleon UK Capital plc offset $1,326,722.81 of the fees associated with the 2023 Registration Statement from the filing fee previously paid by Haleon plc associated with the unsold securities under the 2022 Registration Statement. The Registrants used $469,077.28 of this amount to pay the registration fees owed in connection with the final prospectus supplement of Haleon plc dated March 19, 2024 in relation to the resale of 790,554,820 Ordinary Shares (in the form of Ordinary Shares or American Depositary Receipts representing Ordinary Shares) by Pfizer. Accounting for this transaction, 3,119,828,916 Ordinary Shares were not sold under the 2022 Registration Statement and the 2023 Registration Statement, resulting in an available fee offset of $857,645.53. As a result, $857,645.53 of the previously paid fees remained available for offset prior to the filing of the Registration Statement (File Nos. 333-297789, 333-297789-01 and 333-297789-02) pursuant to which this offering was made. Pursuant to Rule 457(p) under the Securities Act, the Registrants are offsetting $274,657.97 of the fees associated with this offering from the filing fee previously paid by Haleon plc associated with the unsold securities under the 2022 Registration Statement and the 2023 Registration Statement. Following this offset, $582,987.56 of such filing fee remains unused. The Registrants have terminated any offerings that included the unsold securities associated with the claimed offset under the 2022 Registration Statement and 2023 Registration Statement. 2000000000 true